Global Myasthenia Gravis Treatment Market Scope 2024, Forecast To 2033

8 Mar, 2024

The myasthenia gravis treatment market has experienced strong growth, rising from $1.42 billion in 2023 to $1.54 billion in 2024, at a CAGR of 8.1%. This growth is attributed to treatments such as cholinesterase inhibitors, thymectomy procedures, and immunosuppressive therapies. Forecasts indicate continued expansion, reaching $2.05 billion in 2028, with a CAGR of 7.5%. Anticipated developments include biologics, genetic medicine, and emerging immune modulators, with trends focusing on digital therapeutics and collaborative research initiatives.

Global Myasthenia Gravis Treatment Market Key Driver

The surge in myasthenia gravis cases is expected to drive growth in the myasthenia gravis treatment market. This autoimmune neuromuscular disorder causes muscle weakness and fatigue. Treatment involves managing symptoms and providing care to patients. Reports from the National Organization for Rare Disorders and Kermanshah University of Medical Sciences and University Putra Malaysia indicate a prevalence ranging from 12.4 to 40 per 100,000 individuals globally. Consequently, the increasing incidence of myasthenia gravis is contributing to the market's expansion.

Get A Free Sample Of The Global Myasthenia Gravis Treatment Market Report

Global Myasthenia Gravis Treatment Market Segments

The myasthenia gravis treatment market covered in this report is segmented –
1) Treatment:Medication, Surgery, Other Treatments
2) Medication Type:Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) End-Use:Hospitals, Clinics, Other End-Uses
By Geography: The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. North America was the largest region in the myasthenia gravis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Major Myasthenia Gravis Treatment Industry Players

Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Baxter International Inc.; Biogen Idec; Astellas Pharma Inc.; CSL Limited; Chugai Pharmaceutical Co. Ltd.; Grifols S.A; UCB Inc.; Mitsubishi Tanabe Pharma Corp.; Genentech Inc.; Horizon Therapeutics plc; Amneal Pharmaceuticals Inc.; Zydus Lifesciences Limited; Kedrion SpA; CuraVac Inc.; AryoGen Pharmed; RemeGen Co. Ltd.; Kashiv BioSciences LLC; Avadel Pharmaceuticals plc; Immunovant Inc.; Cabaletta Bio Inc.; Argenx SE; NMD Pharma A/S; Cartesian Therapeutics Inc.; DAS Therapeutics Inc.; Harbour BioMed Holdings Ltd.; Zenyaku Kogyo Co. Ltd.; AnTolRx Inc.; CytoDyn Inc.; Ahead Therapeutics

Get The Full Global Myasthenia Gravis Treatment Market Report

Myasthenia Gravis Treatment Market Overview

Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease-causing fatigue and weakness in the skeletal muscles.